LONDON (BLOOMBERG) – New Zealand went to kill an infected child killer with the help of a new type of vaccine.
A decade later, scientists in the South African state found that it could be critical against the advent of sexually transmitted infection: gonorrhea.
That is a huge optimism that rapidly spreading disease could slow down using a vaccine that is already on the market to prevent its bacterial cousin – stress of meningococcal bacteria is renowned for cause potential meningitis epidemics in college deaths, such as the recent on campuses in San Diego and Massachusetts.
Although gonorrhea is not life threatening, it is about to become unstable due to antibiotic resistance.
Doctors also report that congenital species act as associated infections that continue in the throat, where the germs can unfortunately spread through a pig.
That adds to the urgency of finding new ways to prevent the milk, which has expanded its holding on minority groups, including gay men, to the wider community.
He dropped the 19 per cent cases in the United States last year, with similar trends worldwide.
Although there is no immunization against gonorrhea, studies show that a licensed vaccine made by GlaxoSmithKline Plc can offer at least partial protection.
& LOTS OF QUESTIONS & # 39;
"Dr Helen Petousis-Harris, a vaccine at the University of Auckland, has been working closer to the development of a new drug or something similar, who worked with colleagues to show, for the first time, a meningococcal B check had & # 39; to connect to protection against the STI called Compatible with the Clap.
"This has opened an entire work program that needs to be done with many questions to answer."
New Zealand's shot to immunize 1.1 million people from 2004 to 2006 in people six months to 20 years was different from typical meningococcal vaccines.
It is aimed at stimulating antibodies against an additional feature that is common to both germs called outer membrane bikes. Scientists can guess this as an important source of cross defense.
Nobody knows again how cross-defense could work or for how long. Responding to those questions is key to deciding whether vaccines targeting these external membrane clips, such as Glaxo, may help to mitigate the spread of gonorrhea.
& # 39; UNPACKING THE MAGIC & # 39;
"Basically, it's dumping the magic to find out what it is," said Dr Petousis-Harris over the telephone from Auckland.
His paper in the Lancet medical magazine estimated that the vaccination against meningococcal B led to a 31 per cent efficiency against gonorrhea.
That was an interest in the field, according to researchers at the National Institute for Allergy and Infectious Diseases and the University of Uniform Services in Maryland.
"Although Bexsero is the exact answer, we are much closer to the solution of a gonrherhea vaccine than we have been in a long time," said Dr Leah Vincent, a scientist at the organization, in a telephone interview.
YOU US $ 166
GlaxoSmithKline has not yet decided whether to target Gonorrhea with Bexsero, and is expected to generate $ 780 million (S $ 1.07 billion) in sales this year as a meningococcal B vaccine only. The retail price product in the US is about US $ 166 per dose.
The drug maker reviews the results of independent studies and talks to health authorities and external researchers about evaluating Bexer's as a way of preventing gonorrhea, the company said in London in an e-mail response to questions.
In the meantime, he develops the development of the antibiotic etching to treat the disease after completing two mid-stage studies.
"GSK is aware of the increasing public health need for gonorrhea prevention, especially in the light of antimicrobial resistance, and looks at ways of contributing our expertise to the important issue this, "said the company.
Gonorrhea cases have jumped six in major cities of Australia over the past decade, and 78 million new infections occur worldwide throughout the year.
The standard two-drug regimen costs US $ 21.66 per treatment in low and medium-sized countries, Dr Vincent and Dr Ann Jerse, from the Uniform Services University, wrote in a paper published in April.
The establishment of a patient trial with a targeted Bexsero dos-target targeted by American adolescent preventing almost 84,000 infections and a total saving of almost US $ 70 million costs.
Sexually transmitted bacteria rapidly develop antibiotic resistance compared to other organisms, Dr Jerse said over the phone.
"Although drugs are under way, there will only be a short-term answer. That's why a vaccine is very important, and it's time now."
Gonorrhea uses a specific protein to defeat the body's first defense line, Dr Jerse and colleagues at the State University Pharmacy College in July, opening a new path to develop antibiotics and new vaccines.
Gonorrhea, an ancient disease recognized in the second century by a Grace doctor, often causes any symptoms, especially in the neck, enabling it to spread anonymous.
After untreated treatment, the disease can cause many complications from infertility to infertility and ectopic, to premature births and blindness.
There are cases of gonorrhea that no standard therapy currently has been detected in Australia and the UK, the House of Commons in London reported in the last month. Health authorities have warned about more extreme cases to come.
"As many diseases, we forget how bad they were," said Dr Kate Seib, who helped to develop Bexsero in Siena, Italy, for Novartis AG, who sold the vaccine to Glaxo in 2015.
"But it does not kill anyone, so people are not always worried."
No study has yet proved that Bexsero can stop gonorrhea, says Dr. Seib.
The findings in New Zealand, Cuba and Quebec show a link between the vaccine and a reduction in the gonrherhea is "very promising, but just observing," he said.
A quick way to find out if a vaccine could reduce the risk of gonorrhea would be to test Bexsero in a randomly controlled trial among thousands of gay and bisexual men taking a pill to stop HIV, says Dr. Seib.
Therefore, known as pre-exposure proffylaxis, or PrEP, has helped reduce infections that cause AIDS, but is associated with an annual risk of gonorrhea reaching 40 per cent.
If such a study was successful, the results would need to be validated in a larger general population, which would be "extremely expensive", said Dr Charlene Kahler, head of infection and immunity at the University of Western Australia's Biomedical School of Sciences in Perth.
The bacterial causes of meningococcal and gonorrhea disease share 80-90 percent of their DNA, and the results of studies that use animal models according to the use of Bexsero for gonorrhea control are also.
Still, measuring success is challenging as there is no known way of measuring protection against people's gonorrhea, says Dr Kahler at a telephone interview.
Even a moderate level of vaccine could lead to a "almost explanatory" increase in gonorrhea worldwide and slow down the evolution of drug resistant cases, said Professor Christopher Fairley, director of the Center for Sexual Health in Melbourne.
"We must give the best expect that telling people will reduce the number of partners and using condoms will work because they do not work," he said. # 39; Professor Fairley, who is also a public health professor at the University of Melbourne, Monash, in an interview.
"We must face that reality. We have to start exploring other methods."